RecruitingRecruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
NCT07887971 · Aktis Oncology, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
BActinium-2: A Phase 1b, 2 Part, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Intravenous Administration of a B7-H3 Radiopharmaceutical ([225Ac]Ac AKY 2519) in Participants With B7-H3 Imaging Positive Solid Tumors
About this study
This Phase 1b study consists of two parts.
Part 1 is the dose escalation portion and will investigate ascending doses of \[225Ac\]Ac-AKY-2519 in patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), extensive stage-small cell lung cancer (ES-SCLC), metastatic castration-resistant prostate cancer (mCRPC), head and necks squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), and colorectal cancer (CRC). Part 1 will also incorporate a backfill strategy to evaluate two dose levels further.
Part 2 is the dose expansion portion and aims to assess the efficacy of \[225Ac\]Ac-AKY-2519 in two separate cohorts by indication:
* Cohort A: NSCLC
* Cohort B: Other solid tumors
Eligibility criteria
Inclusion Criteria:
* Age ≥ 18 years
* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC, ES-SCLC, HNSCC, ESCC, CRC or prostatic adenocarcinoma
* Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1
* ECOG Performance Status of 0 or 1
* Adequate end-organ function
* Ability to give informed consent and comply with study requirements
* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids
Exclusion Criteria:
* Prior treatment with a B7-H3 targeted therapy
* Prior treatment with a targeted radiotherapy
* Received an investigational agent within the previous 28 days
* Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy within the previous 28 days
* Impaired cardiac function or clinically significant cardiac disease
* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity
Study design
Enrollment target: 152 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11
Estimated completion: 2033-12
Last updated: 2026-11-02
Interventions
Drug: [225Ac]Ac-AKY-2519 (therapeutic)Drug: [64Cu]Cu-AKY-2519 (imaging)
Primary outcomes
- • Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 (Up to 30 days following last administration of [225Ac]Ac-AKY-2519)
- • Part 1: Occurrence of dose-limiting toxicity (DLT) in participants (From first administration of [225Ac]Ac-AKY-2519 to the end of Cycle 1 (each cycle is 28 days))
- • Part 2: Objective Response Rate (ORR) (Up to 30 days following last administration of [225Ac]Ac-AKY-2519)
Sponsor
Aktis Oncology, Inc. · industry
Contacts & investigators
ContactTIffany Wang, MD · contact · AKY-2519-02inquiries@aktisoncology.com · 857-239-5333
All locations (2)
Biogenix Molecular, LLCRecruiting
Miami, Florida, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States